Condition: Acute Coronary Syndrome
rs147204125 in
ACOT6 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs1967309 in
ADCY9 gene and
Acute Coronary Syndrome
PMID 25583994 2015 Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.
rs7412 in
APOE gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs147642358 in
ARPC1A gene and
Acute Coronary Syndrome
PMID 25935875 2015 Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
rs11915606 in
BTD gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs117038461 in
CASTOR3 gene and
Acute Coronary Syndrome
PMID 25935875 2015 Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
rs147233090 in
CATSPER2P1 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs12740374 in
CELSR2 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs35610040 in
CST3 gene and
Acute Coronary Syndrome
PMID 24952865 2014 Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study.
rs188845491 in
CYP3A51P;CYP3A7-CYP3A51P;CYP3A7;ZSCAN25 gene and
Acute Coronary Syndrome
PMID 25935875 2015 Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
rs144610116 in
FAM114A1 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs138741635 in
FHIT gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs11638352 in
FRMD5 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs148121703 in
GABRB1 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs145044782 in
GLCCI1 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs16985615 in
LOC107985383 gene and
Acute Coronary Syndrome
PMID 24952865 2014 Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study.
rs4357117 in
LOC107986540 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs181937009 in
LOC107986652;LOC100507477 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs10455872 in
LPA gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs76863441 in
PLA2G7 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs11057830 in
SCARB1 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs151269874 in
TMEM231 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs57578064 in
TOMM5 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs190543502 in
TP53BP1 gene and
Acute Coronary Syndrome
PMID 28753643 2017 Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
rs61361928 in
UGT2B7 gene and
Acute Coronary Syndrome
PMID 25935875 2015 Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.